David Armstrong

David Armstrong, a Senior reporter for ProPublica, dives into the troubling world of the pharmaceutical industry, spotlighting the exorbitant cost of the cancer drug Revlimid. He discusses how this $1,000-a-pill treatment only costs a mere 25 cents to produce. Armstrong reveals the devious strategies companies employ to maintain high prices and fend off competitors. He also sheds light on the hurdles patients face with insurance denials for necessary treatments, exposing the systemic flaws in the healthcare system.

David Armstrong, an investigative reporter at ProPublica and author of "The Price of Remission," dives into the staggering costs of life-saving medications like Revlimid. He highlights the shocking disparity between the mere 25-cent production cost and the thousand-dollar price tag, raising ethical concerns about drug pricing. Armstrong also shares the emotional toll on patients and the quest for reforms, as well as the complex history of Revlimid's development. His insights illuminate the ongoing struggles within America’s healthcare system.

David Armstrong, a ProPublica health-care reporter battling a rare blood cancer, dives into the shocking pricing of the cancer drug Revlimid. He reveals how this lifesaving medication, costing mere cents to produce, is sold to patients for nearly $1,000 per pill. Armstrong discusses the monopolistic tactics of pharmaceutical companies that keep prices high and access low. He also explores the troubling history of related drugs and the broader implications of America's drug pricing crisis, urging a need for reform in the healthcare system.